Related Experiment Video
Updated: Feb 3, 2026
Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
Published on: September 7, 2022
Eltrombopag For Immune Thrombocytopenic Children in a Single Region
Göksel Leblebisatan1, Yurdanur Kilinc1, Metin Cil1
11Department of Pediatric Hematology, Çukurova University Medical Faculty, Adana, Turkey.
Insights
Eltrombopag, a thrombomimetic agent, improved platelet counts and reduced bleeding in children with chronic immune thrombocytopenia. This offers a new treatment option when standard therapies are insufficient.
Area of Science:
- Pediatric Hematology
- Clinical Pharmacology
Background:
- Chronic immune thrombocytopenia (ITP) in children can be severe and resistant to standard treatments.
- Eltrombopag, a thrombopoietin receptor agonist, has shown efficacy in adult ITP patients.
- Limited data exists on Eltrombopag's use in pediatric chronic ITP.
Purpose of the Study:
- To evaluate the efficacy and safety of Eltrombopag in children with chronic ITP.
- To assess clinical and laboratory improvements in pediatric patients with severe, refractory thrombocytopenia.
Main Methods:
- A single-center study involving 19 pediatric patients with chronic ITP.
- Patients were treated with Eltrombopag according to international dosing guidelines.
Main Results:
- 58% (11/19) of patients demonstrated a benefit from Eltrombopag treatment.
- Benefits included increased platelet levels to safe ranges and reduced need for rescue treatments for bleeding.
Conclusions:
- Eltrombopag is an effective thrombomimetic treatment option for children with chronic ITP.
- It provides a valuable therapeutic strategy when conventional treatments are inadequate.
Abstract:
Objective Child patients of chronic thrombocytopenic purpura with severe and resistant thrombocytopenia were evaluated to observe whether their clinical or laboratory states improve by one of the thrombomimetic therapeutic agent called Eltrombopag as in adults in a single center of different country from previous studies. Materials and Methods Nineteen patients with chronic immune thrombocytopenia were treated with Eltrombopag to dose in international guidelines. Results Approximately half (11/19:58%) of the patients benefitted from the treatment with Eltrombopag either by an increase of platelet levels at safe levels with a decrease in the frequency of bleedings which needed rescue treatment. Conclusion Thrombomimetic treatment options have strengthened the clinician's hand where the regular treatment options became insufficient.
Related Concept Videos
01:38What is the Immune System?
01:03IR Frequency Region: Fingerprint Region
02:40The Eukaryotic Promoter Region
01:36Humoral Immune Responses
01:17Region of Convergence
01:12Regional Terms
Primarily, the human body has two major regions, the axial and appendicular regions. The axial region comprises regions from the head to the abdomen and makes up the central body axis. In contrast,...